Different drug delivery agents, including synthetic polymers, virus-based vectors, lipid-based vectors, and extracellular vesicles (EVs), have been explored previously.
Clinician-scientists at Stanford have proposed a WNT formulation that, when used in combination with a first-of-its-kind normothermic perfusion device, reconditions marginal organs and enables their safe transplantation.
Fiber photometry, a measurement technique that aggregates fluorescence signal using a fiber optic, is a highly pervasive approach in the field of systems neuroscience to study in vivo brain tissue dynamics during ecologically relevant behavior.
Inventors at Stanford have developed a novel strategy to perform concurrent fluorescence measurements of multiple biological parameters in freely moving and head-restrained animals.
Researchers at Stanford have found that applying pressure to macroencapsulation can enhance insulin transport from encapsulated islet beta cells to surrounding tissue and assist in glucose metabolism in type 1 diabetes (T1D) patients.
Genome editing of human hematopoietic stem and progenitor cells (HSPCs) has the potential to create a new class of medication for the treatment of inherited and acquired genetic diseases of the blood and immune system.
Stanford researchers have identified an appropriate method and dosage for radiotherapy-based noninvasive lung volume reduction to treat severe emphysema.
Researchers at Stanford have created a method to differentiate human pluripotent stem cells (hPSCs) into >90% pure hematopoietic stem cell (HSC)-like cells, which serve as progenitors to blood and immune cells.
A new deep-learning system called Atomic Rotationally Equivariant Scorer (ARES) significantly improves the prediction of RNA structures over previous artificial intelligence (AI) models.
Stanford researchers have found that a chemokine receptor antagonist can reduce immunosuppression in the tumor microenvironment and thereby delay tumor progression.
Stanford researchers have developed a new technology, Variant-FlowFISH, to enable high-throughput, highly sensitive measurements of how variants, introduced via CRISPR, affect gene expression.
Stanford researchers have developed a high-affinity IL-11 decoy cytokine for super-agonism and antagonism of the IL-11 receptor, enabling the treatment of a wide variety of diseases from inflammatory disease to cancer as well as research into IL-11 signaling pathways.
Stanford researchers have developed a pioneering gene therapy by targeting reactive astrocytes in the optic nerve head (ONH) and modulating cyclic adenosine monophosphate (cAMP) levels for targeted treatment of glaucoma and other retinal disorders.